The estimated Net Worth of Maria Luisa Maccecchini is at least $8.93 Milión dollars as of 6 February 2023. Maria Maccecchini owns over 52,755 units of Annovis Bio stock worth over $8,927,396 and over the last 4 years he sold ANVS stock worth over $0. In addition, he makes $0 as Executive Board Member at Annovis Bio.
Maria has made over 3 trades of the Annovis Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 52,755 units of ANVS stock worth $7,386 on 6 February 2023.
The largest trade he's ever made was exercising 52,755 units of Annovis Bio stock on 6 February 2023 worth over $7,386. On average, Maria trades about 7,408 units every 35 days since 2020. As of 6 February 2023 he still owns at least 1,040,489 units of Annovis Bio stock.
You can see the complete history of Maria Maccecchini stock trades at the bottom of the page.
Dr. Maria L. Maccecchini Ph.D. serves as Executive Board Member of the Company. Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Founder and CEO of Annovis (f.k.a. Symphony Pharmaceuticals) focused on protecting brain cells after stroke. It sold in 2001 to Transgenomic.
Maria's mailing address filed with the SEC is 1920 MCKINNEY AVENUE, 7TH FLOOR, , DALLAS, TX, 75201.
Over the last 5 years, insiders at Annovis Bio have traded over $0 worth of Annovis Bio stock and bought 24,481 units worth $662,591 . The most active insiders traders include Michael B Hoffman, Maria Luisa Maccecchini a Jeffrey Brian Mc Groarty. On average, Annovis Bio executives and independent directors trade stock every 138 days with the average trade being worth of $158,018. The most recent stock trade was executed by Maria Luisa Maccecchini on 6 February 2023, trading 52,755 units of ANVS stock currently worth $7,386.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio executives and other stock owners filed with the SEC include: